Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8577697 | 0.88 | RAB9A (0.64) | LMNARAB9AALDH1A1NPSR1CA12 | |
| SCHEMBL8574580 | 0.87 | RAB9A (0.65) | LMNARAB9AALDH1A1NPSR1CA12 | |
| SCHEMBL28443002 | 0.81 | ALDH1A1 (0.56) | LMNAALDH1A1NPSR1CA12CA9 | |
| SCHEMBL8663048 | 0.79 | ALDH1A1 (0.70) | LMNARAB9AALDH1A1CA12CYP1A2 | |
| SCHEMBL19862467 | 0.79 | ALDH1A1 (0.58) | LMNAALDH1A1L3MBTL1KMT2AHTT | |
| SCHEMBL27245265 | 0.77 | LMNA (0.59) | LMNARAB9AALDH1A1MEN1MAPT | |
| SCHEMBL3969287 | 0.76 | OPRK1 (0.63) | LMNAALDH1A1OPRK1CA12CYP1A2 | |
| SCHEMBL19862469 | 0.76 | ALDH1A1 (0.54) | LMNAALDH1A1L3MBTL1MEN1MAPT | |
| SCHEMBL13426068 | 0.76 | RAB9A (0.62) | LMNARAB9AALDH1A1NPSR1CA12 | |
| SCHEMBL19862468 | 0.75 | ALOX5 (0.51) | LMNAALDH1A1OPRK1CYP3A4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368205-A1 | CHELATE COMPOUNDS | GE HEALTHCARE AS (NO) | 2024-11-07 | — | — | US | disclosed |
| US-11884686-B2 | Chelate compounds | GE HEALTHCARE AS (NO) | 2024-01-30 | — | — | US | disclosed |
| EP-3472163-B1 | CHELATE COMPOUNDS | GE HEALTHCARE AS (NO) | 2020-11-11 | — | — | EP | disclosed |
| US-20190233450-A1 | CHELATE COMPOUNDS | GE HEALTHCARE AS (NO) | 2019-08-01 | — | — | US | disclosed |
| EP-3472163-A1 | CHELATE COMPOUNDS | GE Healthcare AS (NO) | 2019-04-24 | — | — | EP | disclosed |
| CN-109641900-A | Chelate compound | 通用电气医疗集团股份有限公司 | 2019-04-16 | — | — | CN | disclosed |
| WO-2017220610-A1 | CHELATE COMPOUNDS | GE HEALTHACRE AS (NO) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368205-A1 | CHELATE COMPOUNDS | SLC39A3, SLC39A11, MPI | LMNA 4483/4885RAB9A 1616/4885ALDH1A1 3140/4885 |
| US-11884686-B2 | Chelate compounds | SLC39A3, MPI, SLC39A14 | LMNA 4725/4885RAB9A 2310/4885ALDH1A1 4140/4885 |
| US-20190233450-A1 | CHELATE COMPOUNDS | SLC39A3, MPI, SLC39A14 | LMNA 4725/4885RAB9A 2310/4885ALDH1A1 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.